<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440062</url>
  </required_header>
  <id_info>
    <org_study_id>EVIDIMS</org_study_id>
    <nct_id>NCT01440062</nct_id>
  </id_info>
  <brief_title>Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)</brief_title>
  <official_title>Phase II Study of Efficacy of Vitamin D Supplementation in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NeuroCure Clinical Research Center, Charite, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examination of efficacy, safety and tolerability of vitamin D3 in the treatment of Multiple&#xD;
      Sclerosis (MS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy parameters</measure>
    <time_frame>1 day</time_frame>
    <description>efficacy of Vitamin D (high dose) in patients with Multiple Sclerosis compared to low dose of Vitamin D</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; tolerability parameters</measure>
    <time_frame>1 day</time_frame>
    <description>Routine laboratory, vital signs, physical examination, ECG, AE reporting, Quality of Life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Verum (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>verum arm receiving high dose Vitamin D oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verum (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose arm receiving neutral oil and low dose of Vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verum arm receiving Vitamin D oil</intervention_name>
    <description>oil: 20000 IU/g tablet: 400 IU/g every second day</description>
    <arm_group_label>Verum (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day</intervention_name>
    <description>neutral oil and a low dose of vitamin D</description>
    <arm_group_label>Verum (low dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Age between 18 and 65 at randomization&#xD;
&#xD;
          -  Relapsing-remitting MS according to the revised McDonald-Criteria (2005)&#xD;
&#xD;
          -  EDSS ≤ 6,0&#xD;
&#xD;
          -  Stable immunomodulatory treatment for at least 3 months&#xD;
&#xD;
          -  Sufficient birth control (Pearl-Index &lt;1) and negative pregnancy test at&#xD;
             screening/randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other MS-course than RRMS&#xD;
&#xD;
          -  Treatment with high dose vitamin D within 6 months prior to randomization&#xD;
&#xD;
          -  Patients who have received over the last three months prior to randomization, an&#xD;
             immunomodulatory therapy with the exception of IFN-β1b (Betaferon ®)&#xD;
&#xD;
          -  Any condition that could interfere with MRI or other study related investigation&#xD;
&#xD;
          -  Intolerability to Gd-DTPA&#xD;
&#xD;
          -  Hypersensitivity to the drug Colecalciferol&#xD;
&#xD;
          -  Patients with sarcoidosis&#xD;
&#xD;
          -  Presence or history of nephrolithiasis&#xD;
&#xD;
          -  Pseudohypoparathyroidism&#xD;
&#xD;
          -  Clinically relevant dysfunction of liver, bone narrow or kidney defined by the&#xD;
             following laboratory values:&#xD;
&#xD;
               -  HB &lt;8.5 g / dl&#xD;
&#xD;
               -  WBC &lt;2.5 / nl&#xD;
&#xD;
               -  platelet count &lt;100/nl&#xD;
&#xD;
               -  Creatinine clearance by Cockcroft-Gault formula: Cl &lt;110ml/min (male) and Cl&#xD;
                  &lt;95ml/min (female)&#xD;
&#xD;
               -  AST / ALT&gt; 3.5 times higher than the upper reference value&#xD;
&#xD;
               -  bilirubin&gt; 2.0 mg / dl&#xD;
&#xD;
               -  hypercalcaemia&gt; 2.7 mmol / l&#xD;
&#xD;
               -  calcium / creatinine ratio in urine&gt; 1&#xD;
&#xD;
          -  Treatment with hydrochlorothiazide, digitoxin, digoxin, phenytoin, barbiturates&#xD;
&#xD;
          -  Pregnancy or lactation period&#xD;
&#xD;
          -  Participation in any clinical study within 3 months before or at any time during study&#xD;
&#xD;
          -  Any medical, psychiatric or other condition that could interfere with the patient's&#xD;
             ability to understand and give the informed consent, to comply with the protocol or to&#xD;
             finish the study any ruling commitment or placement in an institution&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Markus Dörr, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Charite</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan-Markus Dörr, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite-NeuroCure</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kliniken für Neurologie Teupitz/Lübben, Asklepios Fachkliniken Brandenburg GmbH</name>
      <address>
        <city>Teupitz</city>
        <state>Brandenburg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Praxis</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologisches Facharztzentrum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria Halle-Dölau gGmbH</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sankt Josefs Krankenhaus Potsdam Neurologie</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 19, 2011</study_first_submitted>
  <study_first_submitted_qc>September 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Jan-Markus Dörr</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

